Early day motion tabled by primary sponsor Paul Flynn (Labour), on Tuesday, 8 June 2004, in the House of Commons. It is signed by 45 members in total.

---

SEROXAT (NO. 2)

That this House congratulates New York State Attorney General Eliot Spitzer on his decision to sue the pharmaceutical company GlaxoSmithKline for alleged repeated and persistent fraud by suppressing the results of studies that showed the anti-depressant Seroxat is no more effective, or less effective, than a placebo in treating depression in young people and that the incidence of suicidal tendencies doubled among users in three of the trials; notes in one trial 6.5 per cent. of the sample taking Seroxat developed suicidal tendencies compared to 1.1 per cent. in the placebo group; is shocked to learn that the results were suppressed because GlaxoSmithKline decided that admitting that the drug did not work in children would be commercially unacceptable... as this would undermine the profile of Seroxat; and calls for early action here to conclude the delayed Medicines and Healthcare Products Regulatory Agency investigation into Seroxat.

---

Secondary information

Type

Early day motion

Reference

1320 

Session

2003-04

Subjects

Fraud Paroxetine GlaxoSmithKline Clinical trials Antidepressants Spitzer, Eliot

Link

View this Early day motion on www.parliament.uk